US 12,409,131 B2
Transdermal delivery of dronabinol
Fotios M. Plakogiannis, Whitestone, NY (US); Tamanna Lather, Jersey City, NJ (US); Nisarg Modi, Jersey City, NJ (US); and Marina Borovinskaya, East Brunswick, NJ (US)
Assigned to Pike Therapeutics USA, Inc., Wilmington, DE (US)
Filed by Pike Therapeutics USA, Inc., Wilmington, DE (US)
Filed on Apr. 7, 2021, as Appl. No. 17/225,038.
Application 17/225,038 is a continuation in part of application No. 17/221,667, filed on Apr. 2, 2021.
Application 17/221,667 is a continuation in part of application No. PCT/US2020/054070, filed on Oct. 2, 2020.
Claims priority of provisional application 62/910,255, filed on Oct. 3, 2019.
Prior Publication US 2021/0236417 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/352 (2006.01); A61P 1/08 (2006.01)
CPC A61K 9/0014 (2013.01) [A61K 9/0021 (2013.01); A61K 9/7084 (2013.01); A61K 31/352 (2013.01); A61P 1/08 (2018.01)] 14 Claims
 
1. A pharmaceutical composition in the form of a transdermal matrix patch comprising: dronabinol, wherein the concentration of the dronabinol is from about 1% to about 15% w/w;
wherein the pharmaceutical composition further comprises:
about 10% to about 17% w/w of a solvent comprising propylene glycol;
about 4% to about 10% w/w of a penetration enhancer comprising oleic acid;
about 50% to about 80% w/w of a silicone pressure sensitive adhesive;
at least one suspending agent comprising silicon dioxide;
an antioxidant comprising BHT,
wherein the transdermal matrix patch provides an average flux of the dronabinol of about 0.43 to about 0.93 μg/cm2/hr over at least 6 days.